evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2 questions · 2 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Ocrelizumab vs placebo

Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).

1 finding from 1 review